Big News! Two studies ICON7 and OCEANS for newly diagnosed women and recurrent women respectively and Bevacizumab ( Avastin) were presented.
In a nutshell :
ICON7 ( Carbo/placitaxel + bevacizumab) is showing continued improved progression free survival and improved overall survival. The study ends in 2013.
OCEANS ( Carbo /gemcitabene + bevacizumab ) Showed clinically meaningful benefit in recurrent ovarian cancer.
There was also a report on the effect of screening on ovarian cancer mortality based on the Prostate, Lung,Colorectal, Ovarian (PLOC)cancer randomized screening trial. Conclusion: Screening ( CA-125 + Transvaginal Ultrasound) does not reduce ovarian cancer mortality.
Every Day is a Blessing!